Flag­ship aims to raise $3B; Phe­nom­ic inks an­oth­er phar­ma deal; On­covi­ta gets €8M for can­cer vac­cine

Flag­ship Pi­o­neer­ing eyes $3B fund: The Mod­er­na cre­ator and in­cu­ba­tor of more than 100 star­tups seeks to raise its eighth fund, per a Wednes­day SEC fil­ing. The move comes as the Boston firm ex­pands to the UK and Asia-Pa­cif­ic. Its last fund was a $3.4 bil­lion haul in June 2021. — Kyle LaHu­cik

Phe­nom­ic AI an­nounces sec­ond phar­ma deal: The biotech said Thurs­day that it’s work­ing with Astel­las Phar­ma to fig­ure out whether Phe­nom­ic’s an­ti­bod­ies can en­hance cell ther­a­pies when treat­ing pa­tients with sol­id tu­mors. Fi­nan­cial terms of the deal were not dis­closed. Ear­li­er this week, Boehringer In­gel­heim said it’s pay­ing Phe­nom­ic $9 mil­lion up­front, plus mile­stones worth up to $500 mil­lion, in a bid to find new tar­gets for cer­tain can­cers. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER